By Peter A. McCullough, MD, MPH
By now all Americans have become closet virologists who nod with understanding when hearing family, school, or work discussions about SARS-CoV-2 variants, subvariants, and mutated Spike proteins. Most everyone knows with the influenza vaccine, that the antigens are modified each year in anticipation of the seasonal predominant strain. With COVID-19 vaccine, the company vaccinologists have been playing from behind. So instead of anticipating a future strain, they have developed bivalent boosters against the ancestral Wuhan wild-type strain and previously dominant BA4/BA5. Our CDC Nowcast system showed the Wuhan wild-type strain had been extinct for nearly two years and as of January 14, 2023, BA4/BA5 the previously dominant strains accounted for only 2.6% of subvariants. The new kids on the block are BQ and XBB with 72% of the pie.
These subvariants have learned to escape the antibodies from the bivalent vaccines with great alacrity over a short period of time. In a letter from Miller et al, the authors concede that the bivalent boosters in theory are essentially useless against the newer subvariants.
An estimated 94% of people in the U.S. have been infected with the SARS-CoV-2 virus at least once, according to according to a new paper from researchers at Harvard’s School of Public Health. That means second and third infections are much milder than the first and carry a negligible risk of hospitalization and death.
Thus with essentially no theoretical opportunity for benefit, and continued cumulative risks of myocarditis, blood clots, and neurological damage, the call to pull the COVID-19 vaccines from the market remains well supported from the emerging literature. Dr. McCullough Calls for COVID-19 Vaccines to be Pulled Off the Market, US Senate, Dec 7, 2022.
If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.
Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, Barouch DH. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. N Engl J Med. 2023 Jan 18. doi: 10.1056/NEJMc2214314. Epub ahead of print. PMID: 36652339.